Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FLU-BU-MEL Conditioning for MDS
NCT06247917Phase 2Recruiting
- Sponsor
- Ruijin Hospital
- Start
- Mar 2024
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of melphalan in myelodysplastic syndrome (MDS), sponsored by Ruijin Hospital. Started Mar 2024; status: recruiting.
02
Drugs
melphalan
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT06247917.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06247917.